EZH2 and B-cell non-Hodgkin lymphoma: In previous studies on HDAC inhibitors in B-cell lymphoma, alterations in H3K27me3 levels post-HDAC inhibitor treatment were not significant, which may explain the limited exploration of the combined mechanisms of HDAC inhibitors and EZH2 inhibitors from the perspective of H3K27me3 modifications [35].